HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

cytarabine • fludarabine IV • thiotepa • busulfan

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma (clinicaltrials.gov)

P2, N=12, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Oct 2025

8 days ago

Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

carboplatin • cyclophosphamide • etoposide IV • melphalan • thiotepa

10d

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors. (PubMed, Acta Neuropathol Commun)

Four patients received adjuvant TRK inhibitor therapy (larotrectinib, repotrectinib, or entrectinib), among which three also received chemotherapy (n = 2) or proton therapy (n = 1). This patient had previously experienced relapse after the initial surgery and underwent autologous peripheral blood stem cell therapy with carboplatin/thiotepa and proton therapy. Conclusions Our study clarifies the distinct differences in the pathology and TRK inhibitor response between LGG and HGG with NTRK fusions.

10 days ago

Journal

TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • MDM4 (The mouse double minute 4) • TPM3 (Tropomyosin 3) • TFG (Trafficking From ER To Golgi Regulator) • FKBP15 (FKBP Prolyl Isomerase 15) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • NTRK (Neurotrophic receptor tyrosine kinase) • SPECC1L (Sperm Antigen With Calponin Homology And Coiled-Coil Domains 1 Like) • GKAP1 (G Kinase Anchoring Protein 1) • KIF5A (Kinesin Family Member 5A)

carboplatin • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib) • thiotepa

17d

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies (clinicaltrials.gov)

P2, N=3, Terminated, St. Jude Children's Research Hospital | N=32 --> 3 | Trial completion date: Apr 2027 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Apr 2026 --> May 2024; Principal Investigator left institution

17 days ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date

Jakafi (ruxolitinib) • cyclophosphamide • fludarabine IV • mesna • thiotepa • busulfan • cyclosporine

18d

TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma (clinicaltrials.gov)

P2, N=50, Completed, Sheba Medical Center | Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Jun 2024 | Trial primary completion date: Apr 2024 --> Jun 2024

18 days ago

Trial completion • Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

cytarabine • etoposide IV • melphalan • thiotepa

22d

CD34+ Transplants for Leukemia and Lymphoma (clinicaltrials.gov)

P2, N=100, Not yet recruiting, Guenther Koehne | Trial completion date: Jun 2031 --> Oct 2031 | Trial primary completion date: Jun 2031 --> Oct 2031

22 days ago

Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan

22d

Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation (clinicaltrials.gov)

P2, N=40, Completed, Case Comprehensive Cancer Center | Trial completion date: Jun 2025 --> Jun 2024 | Active, not recruiting --> Completed

22 days ago

Trial completion • Trial completion date

FLT3 (Fms-related tyrosine kinase 3)

fludarabine IV • thiotepa • captisol-enabled melphalan

29d

Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial. (PubMed, J Hematol Oncol)

The combination of a CD45RA-depleted graft and NK-cell addback led to robust immune reconstitution maximizing the GVL effect and allowed for use of a submyeloablative, TBI-free conditioning regimen that was associated with excellent EFS resulting in promising long-term outcomes in this high-risk population. The trial is registered at ClinicalTrials.gov (NCT01807611).

29 days ago

P2 data • Journal

CD34 (CD34 molecule)

cyclophosphamide • sirolimus • melphalan • fludarabine IV • thiotepa

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (clinicaltrials.gov)

P2, N=324, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027

1 month ago

Trial completion date • Trial primary completion date

KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • NF1 (Neurofibromin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1)

Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan

CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML (clinicaltrials.gov)

P2, N=7, Completed, Stanford University | Suspended --> Completed | N=20 --> 7 | Trial completion date: Feb 2026 --> Sep 2023 | Trial primary completion date: Feb 2025 --> Sep 2023

1 month ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)

cyclophosphamide • fludarabine IV • thiotepa • busulfan

2ms

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov)

P2, N=1, Terminated, Fred Hutchinson Cancer Center | The study was originally intended to be multi-site but was only conducted at the lead site. Due to the rarity of the subject population & smaller # of enrolling sites, we were not able to reach accrual goals.

2 months ago

Enrollment change • Trial termination

cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)

2ms

Successful Treatment of Refractory or Relapsed Hepatoblastoma With Autologous Hematopoietic Stem Cell Transplantation in Children. (PubMed, J Pediatr Hematol Oncol)

This study suggests autologous HSCT as an effective treatment in pediatric patients with R/R hepatoblastoma. Nevertheless, future large-scale prospective studies are warranted.

2 months ago

Journal

AFP (Alpha-fetoprotein)

carboplatin • etoposide IV • topotecan • melphalan • thiotepa

2ms

NCI-2017-00614: Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)

P2, N=204, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025

2 months ago

Trial completion date • Trial primary completion date • Post-transplantation

cyclophosphamide • fludarabine IV • thiotepa • busulfan

2ms

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (clinicaltrials.gov)

P2, N=324, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | N=103 --> 324

2 months ago

Enrollment open • Enrollment change

Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan

2ms

Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group. (PubMed, Br J Haematol)

This prospective multicentre trial evaluated the safety and the efficacy of a thiotepa/melphalan-based reduced intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT) in children and adolescents with chronic myeloid leukaemia (CML) in chronic phase (CP). At last follow-up, 31 patients are GvHD-free and have stopped immunosuppression. RIC HSCT following pretreatment with TKI is feasible and effective in children and adolescents with CP-CML with an excellent disease-free and TKI-free survival.

2 months ago

Journal

ABL1 (ABL proto-oncogene 1)

melphalan • thiotepa

2ms

HR MB-5: Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma (clinicaltrials.gov)

P1/2, N=29, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Active, not recruiting --> Terminated

2 months ago

Trial termination

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)

carboplatin • temozolomide • cyclophosphamide • etoposide IV • irinotecan • thiotepa

2ms

ABCD-NK: Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML (clinicaltrials.gov)

P1/2, N=48, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

melphalan • fludarabine IV • thiotepa • busulfan • plerixafor

2ms

VERITAS: Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (clinicaltrials.gov)

P2, N=34, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Aug 2023 --> Mar 2024

2 months ago

Trial completion date • Metastases

temozolomide • irinotecan • topotecan • thiotepa

3ms

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)

P1, N=33, Recruiting, City of Hope Medical Center | Initiation date: Mar 2024 --> Sep 2024

3 months ago

Trial initiation date

melphalan • fludarabine IV • thiotepa • Orca-T

3ms

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (clinicaltrials.gov)

P3, N=478, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting

3 months ago

Enrollment open • Surgery

ALK (Anaplastic lymphoma kinase) • TERT (Telomerase Reverse Transcriptase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)

cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane

3ms

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML (clinicaltrials.gov)

P=N/A, N=37, Not yet recruiting, First Affiliated Hospital Xi'an Jiaotong University

3 months ago

New trial

fludarabine IV • thiotepa • busulfan • Duoenda (mitoxantrone liposomal)

3ms

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System (clinicaltrials.gov)

P3, N=70, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024

3 months ago

Trial completion • Trial completion date • Surgery

cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • leucovorin calcium • thiotepa • Neupogen (filgrastim) • methotrexate IV

3ms

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov)

P2, N=10, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Dec 2024 --> Jun 2024

3 months ago

Trial primary completion date

MLL rearrangement • MLL rearrangement

cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)

3ms

A Prospective Study of Whole-Brain RT Combined With Thiotepa Sheath Injection Combined With Systemic Therapy for the Primary Disease in the Treatment of Meningeal Metastases in Solid Tumors (clinicaltrials.gov)

P2, N=20, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

3 months ago

New P2 trial

thiotepa

3ms

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant (clinicaltrials.gov)

P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • CD4 (CD4 Molecule)

TP53 mutation

cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan

3ms

NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)

P2, N=42, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Sep 2024

3 months ago

Trial completion date

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9)

MYCN amplification • IL6 expression

cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane

4ms

P2, N=82, Not yet recruiting, Nantes University Hospital | N=60 --> 82

4 months ago

Enrollment change • Post-transplantation

cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan

4ms

CD34+ Transplants for Leukemia and Lymphoma (clinicaltrials.gov)

P2, N=100, Not yet recruiting, Guenther Koehne | Trial completion date: Mar 2031 --> Jun 2031 | Trial primary completion date: Mar 2031 --> Jun 2031

4 months ago

Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan

4ms

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases (clinicaltrials.gov)

P2, N=54, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)

MLL rearrangement • MLL rearrangement

cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion

4ms

NCI-2018-01752: Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)

P2, N=68, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

4 months ago

Trial completion date • Trial primary completion date

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

cyclophosphamide • methotrexate • fludarabine IV • thiotepa • busulfan • methotrexate IV

4ms

Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)

P1, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

4 months ago

Enrollment closed

cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)

4ms

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. (PubMed, Oncotarget)

Enhanced activation of apoptosis was observed in leukemia patient-derived cell samples exposed to the five-drug combination, suggesting a clinical relevance. The results provide a rationale for clinical trials using these two- and five-drug combinations as part of a conditioning regimen for AML patients undergoing HSCT.

4 months ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • CHEK2 (Checkpoint kinase 2) • CHEK1 (Checkpoint kinase 1) • CASP3 (Caspase 3) • ANXA5 (Annexin A5) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)

Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan

5ms

Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)

P1, N=31, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting

5 months ago

Enrollment open

cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)

5ms

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors (clinicaltrials.gov)

P2, N=9, Terminated, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2024 --> Mar 2024; Low accrual

5 months ago

Trial completion date • Trial termination • Trial primary completion date

TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • NUP214 (Nucleoporin 214) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • DEK (DEK Proto-Oncogene)

TP53 mutation • RUNX1 mutation • KMT2A rearrangement • IKZF1 mutation • MLL mutation • Chr t(9;11)

Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • fludarabine IV • thiotepa • busulfan

5ms

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors (clinicaltrials.gov)

P=N/A, N=44, Completed, Masonic Cancer Center, University of Minnesota | Recruiting --> Completed | N=20 --> 44

5 months ago

Trial completion • Enrollment change

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CD34 (CD34 molecule)

LDH elevation • MYCN amplification • MYCN expression

carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • thiotepa • busulfan

5ms

Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)

P1, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2027 --> Apr 2025 | Trial primary completion date: Feb 2027 --> Apr 2025

5 months ago

Trial completion date • Trial primary completion date

cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)

5ms

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (clinicaltrials.gov)

P1/2, N=12, Recruiting, ExCellThera inc. | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Jun 2026

5 months ago

Trial completion date • Trial primary completion date

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)

cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • dorocubicel (UM171 cell therapy)

5ms

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)

P1, N=40, Recruiting, Stanford University | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025

5 months ago

Trial completion date • Trial primary completion date • Metastases

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor

5ms

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors (clinicaltrials.gov)

P4, N=250, Active, not recruiting, Nationwide Children's Hospital | Recruiting --> Active, not recruiting

5 months ago

Enrollment closed

cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • thiotepa • methotrexate IV

5ms

P2, N=60, Not yet recruiting, Nantes University Hospital

5 months ago

New P2 trial • Post-transplantation

cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan

5ms

Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)

P1, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

5 months ago

Enrollment closed

cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)